U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT07558733) titled 'Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer' on April 17.
Brief Summary: The study is a Phase 1b/2, multi-center, open-label, dose escalation trial evaluating the safety and preliminary efficacy of sapanisertib and serabelisib (PIKTOR) with fulvestrant and/or other anticancer therapies in participants with HR+/HER2- advanced/metastatic breast cancer.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
HR+ HER2- Breast Cancer
Intervention:
DRUG: Serabelisib
Serabelisib is a selective, small molecule inhibitor of PI3Kα.
DRUG: Sapa...